Cargando…
Myotonic Dystrophy: From Molecular Pathogenesis to Therapeutics
Autor principal: | Timchenko, Lubov |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570427/ https://www.ncbi.nlm.nih.gov/pubmed/36233257 http://dx.doi.org/10.3390/ijms231911954 |
Ejemplares similares
-
Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2
por: Timchenko, Lubov
Publicado: (2022) -
GSK3β is a new therapeutic target for myotonic dystrophy type 1
por: Wei, Christina, et al.
Publicado: (2013) -
Myotonic Dystrophies 1 and 2: Complex Diseases with Complex Mechanisms
por: Schoser, Benedikt, et al.
Publicado: (2010) -
Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy
por: Lutz, Maggie, et al.
Publicado: (2023) -
Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1
por: Timchenko, Lubov
Publicado: (2019)